Probiotic in Treatment of Adult Patients With Drug-resistant Epilepsy
NCT ID: NCT05160350
Last Updated: 2022-01-11
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
42 participants
INTERVENTIONAL
2021-04-21
2021-10-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Effect of Probiotic Supplementation in Drug-resistant Epilepsy Patients
NCT03403907
Clinical Study Evaluating the Safety of Lactobacillus Probiotic in Children With Drug Resistant Epilepsy
NCT05539287
Ciprofloxacin in Drug-resistant Epilepsy
NCT04763070
Fecal Microbiota Transplantation for Epilepsy
NCT02889627
An Open-Label Extension Study of the Effectiveness and Safety of the Investigational Compound RWJ-333369 in Patients With Epilepsy
NCT00210522
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Probiotic
Familact 2 plus (Zist takhmir pharmaceutical company, Iran), one capsule per day
Probiotic
Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
Placebo
Similar capsule in shape and size (Zist takhmir pharmaceutical company, Iran), one capsule per day
Probiotic
Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Probiotic
Each probiotic capsule contained combination of lactobacillus and Bifidobacterium species.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* Acute pancreatitis
* Pregnancy
* Breastfeeding
* Being under treatment with corticosteroids
* Being under treatment with antibiotics during 2 months before enrollment
* Need for antibiotic therapy during the study
* Change in anti-seizure medication within the month before enrollment
16 Years
60 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mazandaran University of Medical Sciences
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Nasim Tabrizi
Associate professor of neurology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Bu Ali Sina Hospital
Sari, Mazandaran, Iran
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
6938
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.